Anuradha Thakur

Dr. Anuradha Thakur


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ATAnuradha Thakur
Anuradha Thakur
YCYoon Sun Chun
Yoon Sun Chun
NONatasha October
Natasha October
HYHyun Ok Yang
Hyun Ok Yang
VMVinesh Maharaj
Vinesh Maharaj

29 July 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
ATAnuradha Thakur
Anuradha Thakur
PMPhanankosiMoyo Moyo
PhanankosiMoyo Moyo
CWCarl Johan van der Westhuizen
Carl Johan van der Westhuizen
HYHyun Ok Yang
Hyun Ok Yang
VMVinesh Maharaj
Vinesh Maharaj
Elevated levels of the amylo β-proteins (Aβ), particularly Aβ42, are associated with a high risk of Alzheimer’s disease (AD). The Aβ proteins are produced from cellular processing of the amyloid precursor proteins (APPs). To identify natural products that block the formation of Aβ-proteins from APPs, we previously screened a library of plant extracts and identified Xysmalobium undulaum (Apocynaceae) as a potential plant for further research. Here, we provide a report on the isolation and identification of the active principles from the plant species using a bioassay-guided fractionation. Fractions and resulting pure compounds from the purification process of the extract of X. undulatum were screened in vitro against APPs transfected HeLa cell lines. Three compounds, acetylated glycosydated crotoxogenin (1), xysmalogenin-3, β-d-glucopyranoside (2), and crotoxigenin 3-O-glucopyranoside (3), were subsequently isolated and their structures elucidated using NMR and mass spectrometry. Compound 1, a novel cardenolide, and 2 significantly decreased the Aβ42 levels in a dose-dependent manner while compound 3 was inactive. In silico investigations identified the AD’s β-secretase enzyme, BACE1, as a potential target for these compounds with the glycoside moiety being of significance in binding to the enzyme active site. Our study provides the first report of a novel cardenolide and the potential of cardenolides as chemical scaffolds for developing AD treatment drugs.